CN100389196C - 癌细胞疫苗 - Google Patents

癌细胞疫苗 Download PDF

Info

Publication number
CN100389196C
CN100389196C CNB998153788A CN99815378A CN100389196C CN 100389196 C CN100389196 C CN 100389196C CN B998153788 A CNB998153788 A CN B998153788A CN 99815378 A CN99815378 A CN 99815378A CN 100389196 C CN100389196 C CN 100389196C
Authority
CN
China
Prior art keywords
cell
cells
mhc class
molecule
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998153788A
Other languages
English (en)
Chinese (zh)
Other versions
CN1332799A (zh
Inventor
徐民桢
丘刚
罗伯特·汉弗莱斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Publication of CN1332799A publication Critical patent/CN1332799A/zh
Application granted granted Critical
Publication of CN100389196C publication Critical patent/CN100389196C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNB998153788A 1998-12-04 1999-11-24 癌细胞疫苗 Expired - Fee Related CN100389196C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/205,995 1998-12-04
US09/205,995 US6368855B1 (en) 1996-06-11 1998-12-04 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression

Publications (2)

Publication Number Publication Date
CN1332799A CN1332799A (zh) 2002-01-23
CN100389196C true CN100389196C (zh) 2008-05-21

Family

ID=22764546

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998153788A Expired - Fee Related CN100389196C (zh) 1998-12-04 1999-11-24 癌细胞疫苗

Country Status (10)

Country Link
US (2) US6368855B1 (https=)
EP (1) EP1135482B1 (https=)
JP (1) JP4836327B2 (https=)
KR (1) KR100689429B1 (https=)
CN (1) CN100389196C (https=)
AT (1) ATE374817T1 (https=)
AU (1) AU771580C (https=)
CA (1) CA2354188C (https=)
DE (1) DE69937252D1 (https=)
WO (1) WO2000034467A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198626A1 (en) * 2002-04-22 2003-10-23 Antigen Express, Inc. Inhibition of Ii expression in mammalian cells
US20060008448A1 (en) * 1996-06-11 2006-01-12 Minzhen Xu Inhibition of li expression in mammalian cells
EP1270732A1 (en) * 2001-06-21 2003-01-02 Schuler, Gerold Improved transfection of eukaryontic cells with linear polynucleotides by electroporation
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
US11243494B2 (en) 2002-07-31 2022-02-08 Abs Global, Inc. Multiple laminar flow-based particle and cellular separation with laser steering
US20040161417A1 (en) * 2002-08-14 2004-08-19 Eli Gilboa Method of enhancing CD4+ T cell responses
US20060172315A1 (en) * 2005-02-01 2006-08-03 Anderson Amy L Methods for staining cells for identification and sorting
US20060265485A1 (en) * 2005-05-17 2006-11-23 Chai Sek M Method and apparatus for controlling data transfer in a processing system
US7603492B2 (en) * 2005-09-20 2009-10-13 Motorola, Inc. Automatic generation of streaming data interface circuit
EP1991677A2 (en) 2006-01-26 2008-11-19 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
US20080120497A1 (en) * 2006-11-20 2008-05-22 Motorola, Inc. Automated configuration of a processing system using decoupled memory access and computation
US20090060889A1 (en) * 2007-03-12 2009-03-05 Von Hofe Eric Ii-RNAi involved Ii suppression in cancer immunotherapy
US10908066B2 (en) 2010-11-16 2021-02-02 1087 Systems, Inc. Use of vibrational spectroscopy for microfluidic liquid measurement
US8961904B2 (en) 2013-07-16 2015-02-24 Premium Genetics (Uk) Ltd. Microfluidic chip
US11796449B2 (en) 2013-10-30 2023-10-24 Abs Global, Inc. Microfluidic system and method with focused energy apparatus
US10180388B2 (en) 2015-02-19 2019-01-15 1087 Systems, Inc. Scanning infrared measurement system
US11331670B2 (en) 2018-05-23 2022-05-17 Abs Global, Inc. Systems and methods for particle focusing in microchannels
EP3899489B1 (en) 2018-12-21 2025-04-09 ABS Global, Inc. System and methods for sub-population identification
EP3955735B1 (en) 2019-04-18 2024-05-22 ABS Global, Inc. System and process for continuous addition of cryoprotectant
US11628439B2 (en) 2020-01-13 2023-04-18 Abs Global, Inc. Single-sheath microfluidic chip
WO2022087299A1 (en) 2020-10-21 2022-04-28 Abs Global, Inc. Methods and systems for processing genetic samples to determine identity or detect contamination
US12135270B2 (en) 2020-11-23 2024-11-05 Abs Global, Inc. Modular flow cytometry systems and methods of processing samples
USD1118965S1 (en) 2021-11-12 2026-03-17 Abs Global, Inc. Flow cytometry device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US5858776A (en) * 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
CA2253877A1 (en) * 1997-03-07 1998-11-09 Mochida Pharmaceutical Co., Ltd. Antisense compounds to cd14
WO1998050540A1 (en) * 1997-05-05 1998-11-12 Hoechst Marion Roussel Deutschland Gmbh MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726020A (en) * 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis

Also Published As

Publication number Publication date
KR100689429B1 (ko) 2007-03-08
KR20010089545A (ko) 2001-10-06
US6368855B1 (en) 2002-04-09
JP2002531582A (ja) 2002-09-24
AU771580C (en) 2005-08-04
JP4836327B2 (ja) 2011-12-14
EP1135482B1 (en) 2007-10-03
US20030054365A1 (en) 2003-03-20
WO2000034467A1 (en) 2000-06-15
ATE374817T1 (de) 2007-10-15
CN1332799A (zh) 2002-01-23
CA2354188C (en) 2013-07-09
EP1135482A1 (en) 2001-09-26
CA2354188A1 (en) 2000-06-15
DE69937252D1 (de) 2007-11-15
AU1832900A (en) 2000-06-26
AU771580B2 (en) 2004-03-25
EP1135482A4 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
CN100389196C (zh) 癌细胞疫苗
US20020068709A1 (en) Therapeutic uses of LNA-modified oligonucleotides
US5652222A (en) Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides
US20080124366A1 (en) Methods and Compositions for Treating Tumors
US6258790B1 (en) Antisense modulation of integrin α4 expression
WO1998058057A1 (en) Compositions inducing cleavage of rna motifs
US5580969A (en) Antisense oligonucleotides directed against human ICAM-I RNA
JP2002531582A5 (https=)
Temsamani et al. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide
US5596090A (en) Antisense oligonucleotides directed against human VCAM-1 RNA
EP0941317B1 (en) Insulin-like growth factor 1 receptor (igf-1r) antisense oligonucleotide-treated breast cancer cells composition
DE69330137T2 (de) Die kombination von antineoplastischen mitteln und antisense-oligonukleotiden bei der behandlung von krebs
CA2232724A1 (en) Modified protein kinase a-specific oligonucleotides and methods of their use
JPH07501525A (ja) ｃ−ｍｙｂプロトオンコジーンに対するアンチセンスオリゴヌクレオチドによる黒色腫の処置
WO2020157014A1 (en) Antisense oligonucleotides for the treatment of leber's congenital amaurosis
Brenner Hematological malignancies
CA2223109A1 (en) Use of antisense oligonucleotides to il-6 receptor mrna to inhibit cellular proliferation
Wickstrom Nuclease-Resistant DNA Therapeutics
US20030092646A1 (en) Method and reagent for the inhibition of CD20
KR20240082367A (ko) 치료학적 물질로서 고리형 구조의 올리고뉴클레오티드

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080521

Termination date: 20151124